Nordic Bioscience to make its precision medicine biomarker PRO-C3 available in China for research use only (RUO) in the first quarter of 2024.

Contributed by: PR Newswire

Images

PR Newswire associated0

PR Newswire associated1

Tags

Nordic-Bioscience

More Like This

PR Newswire associated0

Nordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseases

T-cell therapy developer, Cbio A/S Unveils 2023 Annual Report Amid Clinical Trial Preparations, Signaling Major Shift to Clinical Stage with DKK40M Financing Secured

PR Newswire associated0

Menarini Silicon Biosystems announces publication of the DETECT III trial results highlighting the potential clinical utility of HER2 testing in circulating tumor cells with CELLSEARCH

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics

PR Newswire associated0

Mindray Expands Its Cardiac Biomarker Portfolio with Cutting-Edge hs-cTnI and NT-proBNP Assays, Empowering Enhanced Cardiovascular Diseases Care

Biognosys Announces Commercial Availability of NULISA™ Proteomics Assay Services for Biomarker Research

Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti-CD40 mAb) Phase I Trial at ESMO 2023

PROTEINA Co., Ltd. Announces Breakthrough Research Published in Nature Biomedical Engineering